魏金莲 副教授/硕士生导师
地址：上海市奉贤区海思路999号华东理工大学实验五楼309室
Email：weijinlian678@ecust.edu.cn
邮编：200237
个人简介
2017年6月毕业于中国药科大学药学院，获理学博士学位；2017年7月进入华东理工大学药学院承担思政工作；2020年1月进入华东理工大学药学博士后科研流动站从事博士后研究，合作导师为李剑教授。2022年7月出站留校工作，加入CJ学者李剑教授团队，从事教学科研工作。
研究方向主要致力于抗肿瘤候选新药的研发，作为主要参与者完成了多个抗肿瘤活性化合物设计合成、药效评价、机制研究的项目，建立了完备的从“体外抗肿瘤表型筛选→机制确证与化学生物学研究→结构修饰与构效关系研究→动物药效与成药性评价”的技术平台体系。近年来，以第一/通讯作者在Acta Pharm. Sin. B、Cell Death Dis.、Eur. J. Med. Chem.等国内外知名学术期刊发表多篇SCI文章，申请发明专利4项（授权1项）。入选2020年上海市“超级博士后”激励计划，同年获得国家自然科学基金青年科学基金项目。
教育经历
2012.09–2017.06，中国药科大学，药学院，制药工程学，硕博，导师：尤启冬教授；
2008.09–2012.06，中国药科大学，药学院，制药工程，学士。
工作经历
2024.2-至今，华东理工大学，药学院，副教授；
2022.08–2024.1，华东理工大学，药学院，讲师；
2020.01–2022.07，华东理工大学，药学院，博士后，合作导师：李剑教授；
2017.07–2019.12，华东理工大学，药学院，思政；
主要研究方向
1. 老药新用与老药二次研发
2. 抗肿瘤创新药物的研发与新靶标机制研究
获奖成果
1. 2023年，华东理工大学青年五四奖章（个人）。
2. 2022年，第八届中国国际“互联网﹢”大学生创新创业大赛，国家级铜奖，指导教师。
3. 2022年，第十三届““挑战杯”全国大学生创业计划竞赛，上海赛区银奖，指导教师。
4. 2021年，第七届中国国际“互联网﹢”大学生创新创业大赛，上海赛区银奖，指导教师。
代表性论文(#共同第一作者，*为通讯作者)
1. Yumo Zhao; Yi Wan; Qiyang Yuan; Jinlian Wei*; Yongqiang Zhang*. Photocatalytic C−Si Bond Formations Using Pentacoordinate Silylsilicates as Silyl Radical Precursors: Synthetic Tricks Using Old Reagents, Org. Lett. 2023, 25: 1386-1391.
2. JinlianWei#, Yongyun Li#,Ruoxi Li, Xin Chen, Tiannuo Yang, Liang Liao, YuqingXie, Jin Zhu, Fei Mao, Renbing Jia*, Xiaofang Xu*, Jian Li*. Drug Repurposing of Propafenone to Discover Novel Anti-tumor Agents by Impairing Homologous Recombination to Delay DNA Damage Recovery of Rare Disease Conjunctival Melanoma. Eur. J. Med. Chem. 2023, 250, 115238.
3. Jinlian Wei#, Xin Chen#, Yongyun Li#, Ruoxi Li, Keting Bao, Liang Liao, Yuqing Xie, Tiannuo Yang, Jin Zhu, Fei Mao, Shuaishuai Ni, Renbing Jia*, Xiaofang Xu*, Jian Li*. Cucurbitacin B-induced G2/M cell cycle arrest of conjunctival melanoma cells mediated by GRP78-FOXM1-KIF20A pathway. Acta Pharm. Sin. B. 2022, 12(10):3861-3876.
4. Keting Bao#, Yongyun Li#, Jinlian Wei#, Ruoxi Li, Jie Yang, Jiahao Shi, Baoli Li, Jin Zhu, Fei Mao*, Renbing Jia*, Jian Li*. Fangchinoline suppresses conjunctival melanoma by directly binding FUBP2 and inhibiting the homologous recombination pathway. Cell Death Dis. 2021, 12 (4), 380.
5. Xin Chen#, Xi Yang#, Fei Mao#, Jinlian Wei#, Yixiang Xu, Baoli Li, Jin Zhu, Shuaishuai Ni*, Lijun Jia*, Jian Li*. Development of novel benzimidazole-derived neddylation inhibitors for suppressing tumor growth invitro and in vivo. Eur. J. Med. Chem. 2021, 210, 112964.
6. Jinlian Wei, Yingrui Yang, Mengchen Lu, Yonghua Lei, Lili Xu, Zhengyu Jiang, Xiaoli Xu, Xiaoke Guo, Xiaojin Zhang, Haopeng Sun*, Qidong You, Recent Advances in the Discovery of HIF-1alpha-p300/CBP Inhibitors as Anti-Cancer Agents. Mini-Rev. Med. Chem. 2018, 18 (4), 296-309.
7. Jinlian Wei, Yingrui Yang, Yali Li, Xiaofei Mo, Xiaoke Guo, Xiaojin Zhang, Xiaoli Xu, Zhengyu Jiang, Qidong You*, Synthesis and evaluation of N-(benzofuran-5-yl)aromaticsulfonamide derivatives as novel HIF-1 inhibitors that possess anti-angiogenic potential, Bioorg.Med. Chem. 2017, 25 (6): 1737-1746.
8. Xiaoli Xu, Yingrui Yang, Xiaofei Mo, Jinlian Wei, Xiaojin Zhang, Qidong You*, Design, synthesis, and evaluation of benzofuran derivatives as novel anti-pancreatic carcinoma agents via in terfering the hypoxia environment by targeting HIF-1alpha pathway, Eur. J. Med. Chem. 2017, 137: 45-62.
9. Jinlian Wei, Yingrui Yang, Mengchen Lu, Lili Xu, Fang Liu, Zhenwei Yuan, Qichao Bao, Zhengyu Jiang, Xiaoli Xu, Xiaoke Guo, Xiaojin Zhang, Qidong You*, Haopeng Sun*, Escape, or Vanish: Control the Fate of p53 through MDM2-Mediated Ubiquitination. Anticancer Agents Med. Chem. 2015, 16 (2): 174-189.
10. Yingrui Yang, Jinlian Wei, Xiaofei Mo, Zhenwei Yuan, Jialing Wang, Chao Zhang, Yieyue Xie, Qidong You*, Haopeng Sun*, Discovery and optimization of new benzofuran derivatives against p53-independent malignant cancer cells through inhibition of HIF-1 pathway. Bioorg Med Chem Lett.2016, 26 (11): 2713-2718.
11. Xin Xue, Jinlian Wei, Lili Xu, Meiyang Xi, Xiaoli Xu, Fang Liu, Xiaoke Guo, Lei Wang, Xiaojin Zhang, Mingye Zhang, Mengchen Lu, Haopeng Sun*, Qidong You*, Effective screening strategy using ensembled pharmacophore models combined with cascade docking: application to p53-MDM2 interaction inhibitors. J Chem Inf Model.2013, 53 (10): 2715-2729.
